277 related articles for article (PubMed ID: 24669276)
1. Noninvasive theranostic imaging of HSV1-sr39TK-NTR/GCV-CB1954 dual-prodrug therapy in metastatic lung lesions of MDA-MB-231 triple negative breast cancer in mice.
Sekar TV; Foygel K; Ilovich O; Paulmurugan R
Theranostics; 2014; 4(5):460-74. PubMed ID: 24669276
[TBL] [Abstract][Full Text] [Related]
2. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Sekar TV; Foygel K; Willmann JK; Paulmurugan R
Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy.
Devulapally R; Lee T; Barghava-Shah A; Sekar TV; Foygel K; Bachawal SV; Willmann JK; Paulmurugan R
Nanomedicine (Lond); 2018 May; 13(9):1051-1066. PubMed ID: 29790803
[TBL] [Abstract][Full Text] [Related]
4. STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.
Kuo WY; Hwu L; Wu CY; Lee JS; Chang CW; Liu RS
Theranostics; 2017; 7(3):647-663. PubMed ID: 28255357
[TBL] [Abstract][Full Text] [Related]
5. SP94-Targeted Triblock Copolymer Nanoparticle Delivers Thymidine Kinase-p53-Nitroreductase Triple Therapeutic Gene and Restores Anticancer Function against Hepatocellular Carcinoma in Vivo.
Sukumar UK; Rajendran JCB; Gambhir SS; Massoud TF; Paulmurugan R
ACS Appl Mater Interfaces; 2020 Mar; 12(10):11307-11319. PubMed ID: 32048820
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
7. Repurposing
Ruiz de Garibay G; García de Jalón E; Stigen E; Lund KB; Popa M; Davidson B; Safont MM; Rygh CB; Espedal H; Barrett TM; Haug BE; McCormack E
Theranostics; 2021; 11(12):6044-6057. PubMed ID: 33897898
[TBL] [Abstract][Full Text] [Related]
8. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ
Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510
[TBL] [Abstract][Full Text] [Related]
9. Theranostic Imaging of Cancer Gene Therapy.
Sekar TV; Paulmurugan R
Methods Mol Biol; 2016; 1461():241-54. PubMed ID: 27424910
[TBL] [Abstract][Full Text] [Related]
10. Advances in imaging gene-directed enzyme prodrug therapy.
Bhaumik S
Curr Pharm Biotechnol; 2011 Apr; 12(4):497-507. PubMed ID: 21342105
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells.
Li LQ; Shen F; Xu XY; Zhang H; Yang XF; Liu WG
ScientificWorldJournal; 2013; 2013():951343. PubMed ID: 23533367
[TBL] [Abstract][Full Text] [Related]
12. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.
Lukashev AN; Fuerer C; Chen MJ; Searle P; Iggo R
Hum Gene Ther; 2005 Dec; 16(12):1473-83. PubMed ID: 16390278
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
14. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
16. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Characterization of 9-(4-[
Fuchigami T; Haywood T; Gowrishankar G; Anders D; Namavari M; Wardak M; Gambhir SS
Mol Imaging Biol; 2020 Oct; 22(5):1151-1160. PubMed ID: 32691392
[TBL] [Abstract][Full Text] [Related]
18. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
Bridgewater JA; Springer CJ; Knox RJ; Minton NP; Michael NP; Collins MK
Eur J Cancer; 1995 Dec; 31A(13-14):2362-70. PubMed ID: 8652270
[TBL] [Abstract][Full Text] [Related]
19. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
McNeish IA; Green NK; Gilligan MG; Ford MJ; Mautner V; Young LS; Kerr DJ; Searle PF
Gene Ther; 1998 Aug; 5(8):1061-9. PubMed ID: 10326029
[TBL] [Abstract][Full Text] [Related]
20. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
Chung-Faye G; Palmer D; Anderson D; Clark J; Downes M; Baddeley J; Hussain S; Murray PI; Searle P; Seymour L; Harris PA; Ferry D; Kerr DJ
Clin Cancer Res; 2001 Sep; 7(9):2662-8. PubMed ID: 11555577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
